What revenue did REIG JOFRE report for H1 2026?

REIG JOFRE reported revenue of €168.5 million for H1 2026, up 1% compared with H1 2025. The company said this was achieved despite the temporary impact of disruption to Forté Pharma’s supply chain in France and Belgium, which was resolved in June.

How profitable was REIG JOFRE in the first half of 2026?

REIG JOFRE reported gross profit of €100.1 million, representing a gross margin of 59.4%, and consolidated EBITDA of €17.9 million, up 27% versus H1 2025. The EBITDA margin improved to 10.7%.

What was REIG JOFRE’s net income in H1 2026?

REIG JOFRE reported consolidated net income of €3.4 million for H1 2026, up 126% compared with the same period of the previous year. The result was achieved despite higher financial expenses and an asset impairment charge, whose recovery is expected during the year as insurance proceeds are collected.

What was REIG JOFRE’s net debt at the end of H1 2026?

REIG JOFRE reported net financial debt of €117.7 million and a net financial debt-to-EBITDA ratio of 3.4x. The ratio included debt allocated to new biotechnology investments.

What drove REIG JOFRE’s H1 2026 performance?

REIG JOFRE said its performance was supported by commercial momentum in prescription solutions in the osteoarticular and dermatology areas, together with the initial recovery of its antibiotics business. The company also reported continued growth of dalbavancin in Europe.

What happened to Forté Pharma’s supply chain during REIG JOFRE’s first half of 2026?

Forté Pharma’s supply chain in France and Belgium was disrupted temporarily during the first half of 2026 and was fully restored by the end of June. REIG JOFRE said the disruption affected revenue during the period.

What did REIG JOFRE achieve at its Toledo antibiotics facility?

At the end of June, REIG JOFRE obtained regulatory approval for its new penicillin-based injectable antibiotics production line in Toledo and began commercial production. The line began start-up activities and the release of its first batches following approval from the health authorities.

How much could REIG JOFRE’s new Toledo line increase production capacity?

REIG JOFRE said the new Toledo line is expected to increase annual production capacity for injectable penicillin-based products by 50% over the coming years. The company also said it is expected to enhance productivity, provide greater operating flexibility and support the competitiveness of essential antibiotics supplied across several European countries.

How did REIG JOFRE’s antibiotics sales perform in the second quarter of 2026?

REIG JOFRE said antibiotics sales rose 16% in the second quarter compared with the same period of 2025. The company attributed the increase in production capacity to support from the new Toledo line.

When is REIG JOFRE’s new Toledo production line expected to contribute to sales?

REIG JOFRE said the new Toledo antibiotics production line is expected to make a progressively increasing contribution to sales beginning in the second half of 2026. The company also said the line’s production capacity is expected to increase by 50% over the coming years.

What other operational projects did REIG JOFRE report progress on in H1 2026?

REIG JOFRE reported progress in the construction of Leanbio’s new GMP facility and in the development of Syna Therapeutics’ biosimilar. It also said dalbavancin, its latest launch of a non-penicillin injectable antibiotic in Europe, continued to gain traction.

Home
News Intelligence
Laboratorio Reig Jofre S.A.
REIG JOFRE reports €17.9 million EBITDA for H1 2026 as Toledo antibiotics line starts production

Back to all Laboratorio Reig Jofre S.A. press releases

Laboratorio Reig Jofre S.A.

BME:RJF

REIG JOFRE reports €17.9 million EBITDA for H1 2026 as Toledo antibiotics line starts production

Published Friday, 31 July 2026

Get alerts

Plain English summaries when Laboratorio Reig Jofre S.A. announces news.

At a glance

Company: Laboratorio Reig Jofre S.A.
Listings: BME:RJF
Announcement type: Financial results
Published: Friday, 31 July 2026
Reporting period: first half of 2026
Source announcement: reigjofre.com

Key figures
Measure	Figure	Period	Compared with
Revenue	€168.5 million	H1 2026	up 1% vs H1 2025
Gross profit	€100.1 million	H1 2026	Not stated
Consolidated EBITDA	€17.9 million	H1 2026	up 27% vs H1 2025
Consolidated net income	€3.4 million	H1 2026	up 126% vs H1 2025
Net financial debt	€117.7 million	Not stated	Not stated
Antibiotics sales	16%	the second quarter	a 16% rise vs the same period of 2025

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Video summary 1 minute 20 seconds

The video covers the same ground as the plain English summary below.

Announcement Summary

REIG JOFRE reported its financial results for the first half of 2026.

Revenue was €168.5 million; Forté Pharma’s supply-chain disruption in France and Belgium was resolved in June.
Gross profit was €100.1 million, with a 59.4% gross margin.
The announcement states EBITDA of €18 million in its description and €17.9 million in its financial highlights; EBITDA margin was 10.7%.
Net income was €3.4 million despite higher financial expenses and an asset impairment charge; recovery is expected as insurance proceeds are collected.
Net financial debt was €117.7 million, with a 3.4x net financial debt-to-EBITDA ratio.

At the end of June, regulatory approval was obtained for Toledo’s new penicillin-based injectable antibiotics line, which began commercial production. The company expects annual capacity for injectable penicillin-based products to increase by 50% over coming years.

Investor FAQs

REIG JOFRE published its financial results for the first half of 2026. The company reported revenue of €168.5 million, consolidated EBITDA of €17.9 million and consolidated net income of €3.4 million.

Source announcement

Company: Laboratorio Reig Jofre S.A.
Title: REIG JOFRE publishes its H1 2026 financial results
Published: Friday, 31 July 2026
Source site: reigjofre.com

Read the source announcement on reigjofre.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…